Serum sBCMA levels were significantly associated with MM disease burden, supporting sBCMA as a valuable biomarker and highlighting sBCMA as a potential drug sink to abrogate effective BCMA-directed therapies. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.